Method for assessing occupational pesticide exposure seems not to influence risk estimates for prostate cancer, NHL, Parkinson disease
MONDAY, April 18, 2022 (HealthDay News) — The method for assessing occupational pesticide exposure does not appear to influence risk estimates for prostate cancer, non-Hodgkin lymphoma, or Parkinson disease, according to a study published online April 13 in Occupational & Environmental Medicine.
Johan Ohlander, Ph.D., from Utrecht University in the Netherlands, and colleagues examined how the applied exposure assessment method for pesticide exposure influenced risk estimates for chronic diseases. The influence of exposure assessment method type was examined on the summary risk ratio (sRR) of prostate cancer, non-Hodgkin lymphoma, and Parkinson disease in three meta-analyses (25, 29, and 32 studies, respectively). Group-level assessments, self-reported exposures, expert-level assessments, and biomonitoring were the exposure assessment method types examined.
The researchers observed no association for exposure assessment method types with statistically significant differences in sRRs across any of the health outcomes. There was variation in the heterogeneity of the results, from high in cancer studies to moderate and low in Parkinson disease studies. Significantly higher sRR estimates were seen with case-control designs compared with prospective cohort designs. In addition, significantly higher sRR estimates were seen with later versus earlier non-Hodgkin lymphoma studies. Significantly higher sRR estimates were seen for prostate cancer for studies from North America compared with studies from Europe.
“When performing systematic reviews of studies on chronic health effects of occupational pesticide exposure, epidemiological study design, publication year, and region where the study was performed, should primarily be considered,” the authors write.
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer
Focal Therapy Use Remains Uncommon in Nonmetastatic Prostate Cancer
All-Cause Mortality Elevated for Adult Five-Year Survivors of Hodgkin Lymphoma
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Structured Exercise Should Be Considered as Adjunct Therapy for Cancer
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women